Product Description
Bayer is developing BAY-2327949 as a treatment for moderate chronic kidney disease. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04552262)
Mechanisms of Action: V1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Diabetic Nephropathy|Kidney Failure, Chronic|Kidney Diseases
Phase 1: Weight Gain|Kidney Failure, Chronic|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ASSESS-CKD | P2 |
Withdrawn |
Kidney Failure, Chronic|Diabetic Nephropathy |
2022-04-25 |
24% |
| ASSESS-CKD | P2 |
Terminated |
Kidney Diseases |
2021-05-05 |
|
| NCT04552262 | P1 |
Terminated |
Kidney Failure, Chronic |
2020-12-21 |
21% |
| NCT04004195 | P1 |
Completed |
Kidney Diseases|Weight Gain |
2020-02-07 |
27% |